What is the role of ferumoxytol in the evaluation of endoleaks in patients with abdominal aortic aneurysms (AAA) and chronic kidney disease (CKD) who have undergone endovascular aneurysm repair (EVAR)?
Label:chem
Topic
Ferumoxytol is an iron oxide nanoparticle used as a contrast agent in magnetic resonance angiography (MRA). It is particularly useful for patients with chronic kidney disease (CKD) who may not be suitable candidates for Gadolinium-based contrast agents due to the risk of nephrogenic systemic fibrosis. Ferumoxytol has a prolonged blood pool half-life, which enhances its sensitivity in detecting endoleaks, especially small or slow-flow endoleaks.
From: "Evaluation of aortic stent endoleaks in the renally impaired patient with ferumoxytol-enhanced MR angiography", Clinical Imaging, Volume 118, February 2025, 110383
Answer
Ferumoxytol-enhanced MRA (FE-MRA) is a safe, practical, and effective imaging solution for evaluating Type I and Type II endoleaks in patients with AAA and CKD who have undergone EVAR. It provides accurate detection and characterization of endoleaks, allowing for proper clinical management. The study demonstrated that dynamic low-dose and steady-state standard-dose FE-MRA can reliably visualize endoleaks, with no adverse reactions reported.
Return to Home
Chemical List
Knowledge you may be interested in